CINECA IRIS Institutional Research Information System

FERRERO, Dario
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.908
EU - Europa 4.135
AS - Asia 1.829
AF - Africa 65
SA - Sud America 36
OC - Oceania 24
Continente sconosciuto - Info sul continente non disponibili 5
Totale 11.002
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.776
CN - Cina 1.034
IT - Italia 603
DE - Germania 535
RU - Federazione Russa 493
IE - Irlanda 471
SE - Svezia 395
UA - Ucraina 357
FR - Francia 331
FI - Finlandia 260
SG - Singapore 253
KR - Corea 247
GB - Regno Unito 225
AT - Austria 156
PL - Polonia 155
CA - Canada 126
VN - Vietnam 104
IN - India 61
SN - Senegal 41
JP - Giappone 34
BE - Belgio 24
CH - Svizzera 23
ES - Italia 23
TR - Turchia 21
NL - Olanda 18
AU - Australia 17
HK - Hong Kong 17
BR - Brasile 14
AR - Argentina 13
GR - Grecia 13
SA - Arabia Saudita 13
UZ - Uzbekistan 13
DK - Danimarca 12
ZA - Sudafrica 9
TH - Thailandia 8
TW - Taiwan 8
NZ - Nuova Zelanda 7
PT - Portogallo 7
BY - Bielorussia 6
CZ - Repubblica Ceca 6
MU - Mauritius 6
MX - Messico 6
CO - Colombia 4
BN - Brunei Darussalam 3
EU - Europa 3
HU - Ungheria 3
IL - Israele 3
NO - Norvegia 3
RS - Serbia 3
SI - Slovenia 3
DZ - Algeria 2
ID - Indonesia 2
MY - Malesia 2
NG - Nigeria 2
PE - Perù 2
RO - Romania 2
SK - Slovacchia (Repubblica Slovacca) 2
UY - Uruguay 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AP - ???statistics.table.value.countryCode.AP??? 1
BO - Bolivia 1
BW - Botswana 1
IR - Iran 1
KE - Kenya 1
KW - Kuwait 1
LA - Repubblica Popolare Democratica del Laos 1
LI - Liechtenstein 1
LT - Lituania 1
LU - Lussemburgo 1
LV - Lettonia 1
MD - Moldavia 1
MK - Macedonia 1
MW - Malawi 1
NP - Nepal 1
PH - Filippine 1
PK - Pakistan 1
TN - Tunisia 1
UG - Uganda 1
Totale 11.002
Salva come PNG Salva come JPEG
Città #
Beijing 768
Chandler 685
Dublin 466
Houston 402
Ashburn 279
Fairfield 254
Jacksonville 216
Villeurbanne 197
Singapore 187
Medford 186
Ann Arbor 175
Princeton 156
Torino 156
Vienna 154
Wilmington 137
Nyköping 133
Warsaw 130
Woodbridge 129
Dearborn 122
Seattle 95
Cambridge 82
Milan 75
Toronto 72
Dong Ket 64
Pisa 56
Fremont 49
San Mateo 47
Redwood City 43
Turin 43
Boardman 41
Boston 40
Guangzhou 39
Verona 36
New York 35
Hefei 33
Regensburg 32
London 31
Santa Clara 26
Nanjing 24
Norwalk 24
Lachine 23
San Diego 23
Shanghai 21
Brussels 20
Düsseldorf 20
Washington 20
Berlin 17
Frankfurt am Main 17
Helsinki 17
Ottawa 17
Mountain View 16
Rome 16
Falls Church 13
San Jose 13
Hangzhou 12
Istanbul 12
Nürnberg 12
Pune 12
Buenos Aires 11
Chengdu 11
Gorzów Wielkopolski 11
Seoul 11
Duncan 10
Hong Kong 10
Silver Spring 10
Chennai 9
Jeddah 9
Kunming 9
Moscow 9
Munich 9
Napoli 9
Poznan 9
Saga 9
Amsterdam 8
Nanchang 8
Rochester 8
Ankara 7
Changchun 7
Dallas 7
Elsternwick 7
Los Angeles 7
Philadelphia 7
San Francisco 7
Tokyo 7
Upper Marlboro 7
Zhengzhou 7
Athens 6
Birmingham 6
Central District 6
Detroit 6
Fuzhou 6
Guadalajara 6
Hebei 6
Phoenix 6
Sejong 6
São Paulo 6
Alessandria 5
Barcelona 5
Chicago 5
Collegno 5
Totale 6.540
Salva come PNG Salva come JPEG
Nome #
Monoclonal antibody purging and autologous bone marrow transplantation in acute myelogenous leukemia in complete remission. 565
Outcome of lower-risk patients with myelodysplastic syndromes without 5q deletion after failure of erythropoiesis-stimulating agents 561
Corticosteroids can reverse severe imatinib-induced hepatotoxicity 281
The use of erythropoiesis-stimulating agents is safe and effective in the management of anaemia in myelofibrosis patients treated with ruxolitinib 193
FLAI induction regimen in elderly patients with acute myeloid leukemia 186
Ruxolitinib in steroid refractory graft-vs.-host disease: A case report 185
Can pegylated interferon improve the outcome of polycythemia vera patients? 172
Erythroid response during iron chelation therapy in a cohort of patients affected by hematologic malignancies and aplastic anemia with transfusion requirement and iron overload: a FISM Italian multicenter retrospective study 157
A Ph-Negative Myeloproliferative Disorder with JAK2 Mutation Disclosed by Imatinib Therapy in Two Patients with Ph+ CML. 152
A POST-REMISSION MAINTENANCE TREATMENT WITH LOW-DOSE CHEMOTHERAPY + RETINOIDS AND DIHYDROXYLATED VITAMIN D3 MAY IMPROVE THE SURVIVAL OF POOR-PROGNOSIS AML/MDS PATIENTS 148
Anemia in the Elderly: not Always what it Seems. 144
Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice 135
Induction of differentiation in human HL-60 cells by 4-hydroxynonenal, a product of lipid peroxidation. 132
DROPLED DIGITAL PCR MAY HAVE A PROGNOSTIC VALUE FOR PREDICTING RELAPSE AFTER IMATINIB DISCONTINUATION 128
Telomere loss in Philadelphia-negative hematopoiesis after successful treatment of chronic myeloid leukemia: evidence for premature aging of the myeloid compartment. 124
A phase II, multicentre trial of decitabine in higher-risk chronic myelomonocytic leukemia 123
THE COMBINATION OF FLUDARABINE + CITARABINE + IDARUBICIN (FLAI) IS A SAFE AND EFFECTIVE TREATMENT FOR ELDERLY PATIENTS WITH AML OR HIGH RISK MDS 117
Hematopoietic stem and progenitor cell composition in peripheral blood and in mobilized CD34+ cells harvests. 114
Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome 111
Advances in biology of multiple myeloma: cell kinetics, molecular biology and immunology. 108
Terminal differentiation of the human promyelocytic leukemia cell line, HL-60, in the absence of cell proliferation. 107
Effects of erythropoiesis-stimulating agents on overall survival of international prognostic scoring system low/intermediate-1 risk, transfusion-inde-pendent myelodysplastic syndrome patients: A cohort study 105
Incidence and Risk-Factors of Secondary Myelodysplastic Syndrome/Acute Leukemia Following High-Dose Chemotherapy and Autograft: A Long-Term Analysis on 307 Lymphoma Patients 104
Haplo-identical allografting with post-transplant cyclophosphamide in high-risk patients 104
Purification and characterization of two recombinant human granulocyte colony-stimulating factor glycoforms. Pharmacokinetic and activity studies of single-dose administration in mice. 100
Can the revised IPSS predict response to erythropoietic-stimulating agents in patients with classical IPSS low or intermediate-1 MDS? 100
Surface phenotypes of human hemopoietic progenitor cells defined by monoclonal antibodies. 98
TYROSINE KINASE INHIBITORS DISCONTINUATION IN CHRONIC MYELOID LEUKEMIA: A RETROSPECTIVE ANALYSIS OF 208 ITALIAN PATIENTS 97
ROLE OF ALLOGRAFTING IN HIGH RISK ACUTE MYELOID LEUKEMIA 96
The BCR-ABL Transcript Levels At 3 and 6 Months Predict the Long-Term Outcome of Chronic Myeloid Leukemia Patients Treated Frontline with Imatinib Mesylate: A Gimema CML WP Analysis. 93
Antigenic phenotype of myelomonocytic progenitors (CFU-GM) in chronic myeloproliferative disorders. 91
IMATINIB DISCONTINUATION IN CHRONIC MYELOID LEUKEMIA: A RETROSPECTIVE ANALYSIS ON PATIENTS IN CLINICAL PRACTICE 87
IMATINIB DISCOTINUATION IN CHRONIC MYELOID LEUKEMIA: A RETROSPECTIVE ANALYSIS ON 28 UNSELECTED PATIENTS 86
Trophoblast cell line conditioned medium for in vitro culture and antigenic characterization of acute myeloid leukemia clonogenic cells. 85
The Degree of Telomere Loss in Hematopoietic Cells Correlates with the Risk of Secondary Myelodysplasia/Acute Leukemia Development Following Autologous Stem Cell Transplantation 85
A retrospective real-life analysis of chronic myeloid leukemia patients in suboptimal response to imatinib: three centres experience. 85
Telomerase Inhibitor BIBR1532 Induces Telomere Shortening and Growth Inhibition in Extra-Germinal Center (GC)-Derived Lymphoid Cell Lines 84
A suppressor lymphokine produced by human T leukemia cell lines. Partial characterization and spectrum of activity against normal and malignant hemopoietic cells. 82
Enhancement of methotrexate cytotoxicity by modulation of proliferative activity in normal and neoplastic T lymphocytes and in a myeloid leukemia cell line. 82
The mutation of N-ras oncogene does not involve myeloid and erythroid lineages in a case of multiple myeloma. 82
Real life use of bendamustine in elderly patients with lymphoid neoplasia 81
c-Cbl tyrosine phosphorylation and subcellular localization in human primary leukemic cells. 80
Functional and phenotypic characterization of two HL60 clones resistant to dimethylsulfoxide. 80
Marked telomere shortening in mobilized peripheral blood progenitor cells (PBPC) following two tightly spaced high-dose chemotherapy courses with G-CSF 79
Moderate/ Severe Pleural Effusion As a Side Effect in Very Old Chronic Myeloid Leukemia (CML) Patients Undergoing Imatinib Treatment. 79
A validated real-time quantitative PCR approach shows a correlation between tumor burden and successful ex vivo purging in follicular lymphoma patients. 78
Establishment from an adult leukemic patient of two novel precursor B cell lines with different growth modality. 78
Harlequin granulocyte-colony stimulating factor interleukin 6 molecules with bifunctional and antagonistic activities. 75
Angiocentric lymphoma: a case report. 75
DIFFERENT COMPOSITION OF HEMATOPOIETIC STEM AND PROGENITOR CELLS BETWEEN PERIPHERAL BLOOD AND BONE MARROW: BIOLOGICAL AND CLINICAL IMPLICATIONS 75
Induction of proliferation and NK activity in human lymphocytes by mature myelomonocytic cells: evidence for an HLA-DR-independent MLR stimulatory ability of terminally differentiated nonlymphoid leukemic cell lines and of normal peripheral blood granulocytes. 74
Long-term therapy-free remission in a patient with platelet-derived growth factor receptor beta-rearranged myeloproliferative neoplasm. 74
A novel human lymphokine that inhibits haematopoietic progenitor cell proliferation. 74
Ras oncogene mutation in multiple myeloma. 73
Autologous bone marrow transplantation in acute myeloid leukemia after in-vitro purging with an anti-lacto-N-fucopentaose III antibody and rabbit complement. 73
Early peripheral clearance of leukemia-associated immunophenotypes in AML: centralized analysis of a randomized trial 73
A Retrospective Real-Life Analysis of Chronic Myeloid Leukemia Patients in Suboptimal Response to Imatinib. 72
Age influences initial dose and compliance to imatinib in chronic myeloid leukemia elderly patients but concomitant comorbidities appear to influence overall and event-free survival. 72
ROLE OF ALLOGRAFTING IN HIGH RISK ACUTE MYELOID LEUKEMIA 71
Stem cell factor improvement of proliferation and maintenance of hemopoietic progenitors in myelodysplastic syndromes. 69
A single step density gradient separation for large scale enrichment of mobilized peripheral blood progenitor cells collected for autotransplantation. 69
COEXISTENCE OF A JAK2 MUTATED CLONE MAY CAUSE HEMATOLOGIC RESISTANCE (HRES) TO TIROSYN-KINASE INHIBITORS (TKI) IN CHRONIC MYELOID LEUKEMIA (CML) 69
A retrospective study on 226 polycythemia vera patients: impact of median hematocrit value on clinical outcomes and survival improvement with anti-thrombotic prophylaxis and non-alkylating drugs 68
Differences among young adults, adults and elderly chronic myeloid leukemia patients. 68
Human granulocyte surface molecules identified by murine monoclonal antibodies. 67
Long-term follow-up of a trial comparing post-remission treatment with autologous or allogeneic bone marrow transplantation or intensive chemotherapy in younger acute myeloid leukemia patients 67
Immunological separation of two CFU-GM subsets showing different responsiveness to T-cell derived growth factors. 67
Generation of anti-tumour activity by OKT3-stimulation in multiple myeloma: in vitro inhibition of autologous haemopoiesis. 65
Transformation and plasmacytoid differentiation of EBV-infected human B lymphoblasts by ras oncogenes. 64
[Variability of the response to recombinant human erythropoietin in patients undergoing hemodialysis treatment] 63
Induction of differentiation of HL-60 cells by dimethyl sulfoxide: evidence for a stochastic model not linked to the cell division cycle. 63
Survival improvement of poor-prognosis AML/MDS patients by maintenance treatment with low-dose chemotherapy and differentiating agents. 63
Induction of differentiation of human myeloid leukemias: surface changes probed with monoclonal antibodies. 62
CEP-18770: a novel orally-active proteasome inhibitor with a tumor-selective pharmacological profile competitive with bortezomib 62
Long-Term Follow-up in Very Elderly Patients with Chronic Myeloid Leukemia Treated with Imatinib Frontline 62
Effects of different doses of erythropoietin in patients with myelodysplastic syndromes: A propensity score-matched analysis 62
Randomized trial comparing standard vs sequential high-dose chemotherapy for inducing early CR in adult AML 62
Conditions influencing the expansion of the circulating hemopoietic progenitor cell compartment. 61
Netupitant-palonosetron to prevent chemotherapy-induced nausea and vomiting in multiple myeloma patients receiving high-dose melphalan and autologous stem cell transplantation 61
Can the dismal prognosis of patients with central nervous system plasma cell neoplasms be improved? 61
In patients with Polycythemia Vera older age is the prognostic factor at highest impact on survival 60
Clinical significance of early molecular response in chronic myeloid leukemia patients treated frontline with imatinib mesylate. 60
Antigenically distinct subpopulations of myeloid progenitor cells (CFU-GM) in human peripheral blood and marrow. 60
Immunomodulatory and clinical effects of daratumumab in T-cell acute lymphoblastic leukaemia 60
Subpopulation heterogeneity in human acute myeloid leukemia determined by monoclonal antibodies. 59
Surface phenotype of clonogenic cells in acute myeloid leukemia defined by monoclonal antibodies. 59
Dedifferentiation , maldifferentiation or arrested differentiation in human acute myelogenous leukemia. 58
Sensibilita' delle sottopopolazioni staminali mieloidi (CFU-GM) a CSA di diversa origine. 58
Self-renewal inhibition of acute myeloid leukemia clonogenic cells by biological inducers of differentiation. 56
How many patients can proceed from chronic myeloid leukaemia diagnosis to deep molecular response and long-lasting imatinib discontinuation? A real life experience 56
Imatinib in Very Elderly (> 75 years) CML Patients: Are Low-Doses (<400 mg daily) Enough? 56
Human recombinant stem cell factor stimulates in vitro proliferation of acute myeloid leukemia cells and expands the clonogenic cell pool. 54
Conditions influencing the expansion of the circulating hemopoietic progenitor cell compartment. 54
Cyclic neutropenia and severe hypogammaglobulinemia in a patient with excess of CD8-positive T lymphocytes: response to G-CSF therapy. 53
Increase of telomerase activity and hTERT expression in myelodysplastic syndromes 53
CD9 antigen on acute non-lymphoid leukemia cells: preferential expression by promyelocytic (M3) subtype. 53
A Retrospective Analysis about Frequency of Monitoring in Italian Chronic Myeloid Leukemia Patients after Discontinuation 53
Human leukaemic cell lines 52
Azacitidine for the treatment of patients with acute myeloid leukemia : Report of 82 patients enrolled in an Italian compassionate program 52
Differentiating agents + low-dose chemotherapy in the management of old/poor prognosis patients with acute myeloid leukemia or myelodysplastic syndrome 52
Totale 9.598
Salva come PNG Salva come JPEG
Categoria #
all - tutte 32.014
article - articoli 0
book - libri 0
conference - conferenze 6.406
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 38.420
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.446 0 0 78 112 108 286 171 100 265 162 95 69
2020/20211.293 121 71 117 56 111 58 88 65 177 97 125 207
2021/20221.406 66 66 43 109 43 38 151 73 43 120 313 341
2022/20232.627 243 176 52 193 185 576 194 134 195 508 126 45
2023/20241.112 127 183 59 57 96 179 35 72 17 51 89 147
2024/2025231 33 161 37 0 0 0 0 0 0 0 0 0
Totale 11.406